JP2003506024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003506024A5 JP2003506024A5 JP2001513966A JP2001513966A JP2003506024A5 JP 2003506024 A5 JP2003506024 A5 JP 2003506024A5 JP 2001513966 A JP2001513966 A JP 2001513966A JP 2001513966 A JP2001513966 A JP 2001513966A JP 2003506024 A5 JP2003506024 A5 JP 2003506024A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- hgf
- acid ligand
- seq
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 29
- 239000003446 ligand Substances 0.000 description 20
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 17
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 16
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- JCAQMQLAHNGVPY-UUOKFMHZSA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-(2,2,4-trioxo-1h-imidazo[4,5-c][1,2,6]thiadiazin-7-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical class O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NS(=O)(=O)NC2=O)=C2N=C1 JCAQMQLAHNGVPY-UUOKFMHZSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53642890A | 1990-06-11 | 1990-06-11 | |
| US09/364,539 US6344321B1 (en) | 1990-06-11 | 1999-07-29 | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
| US09/364,543 | 1999-07-29 | ||
| US09/364,543 US6331394B1 (en) | 1991-06-10 | 1999-07-29 | Nucleic acid ligands to integrins |
| US09/364,539 | 1999-07-29 | ||
| PCT/US2000/020139 WO2001009159A1 (en) | 1990-06-11 | 2000-07-24 | Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003506024A JP2003506024A (ja) | 2003-02-18 |
| JP2003506024A5 true JP2003506024A5 (enExample) | 2007-09-13 |
Family
ID=48986297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001513966A Pending JP2003506024A (ja) | 1990-06-11 | 2000-07-24 | 肝細胞増殖因子／細胞分散因子（ＨＧＦ）又はその受容体ｃ−ｍｅｔ、及びインテグリン類に対する核酸リガンド |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6344321B1 (enExample) |
| EP (1) | EP1203007B1 (enExample) |
| JP (1) | JP2003506024A (enExample) |
| CA (1) | CA2381004A1 (enExample) |
| WO (1) | WO2001009159A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070166741A1 (en) | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| US7645743B2 (en) * | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
| CA2328356A1 (en) * | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
| EP2325337A1 (en) * | 2000-09-26 | 2011-05-25 | Duke University | RNA aptamers and methods for identifying the same |
| US20030118585A1 (en) | 2001-10-17 | 2003-06-26 | Agy Therapeutics | Use of protein biomolecular targets in the treatment and visualization of brain tumors |
| JP4773684B2 (ja) | 2001-05-25 | 2011-09-14 | デューク ユニバーシティ | 薬物のモジュレータ |
| DK1409506T3 (da) * | 2001-07-23 | 2012-08-06 | Univ Leland Stanford Junior | Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr |
| US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| WO2004001065A2 (en) * | 2002-06-24 | 2003-12-31 | Cornell Research Foundation, Inc. | Exhaustive selection or rna aptamers against complex targets |
| US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US7670631B2 (en) * | 2003-03-12 | 2010-03-02 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists |
| WO2004094614A2 (en) * | 2003-04-21 | 2004-11-04 | Archemix Corp. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| ATE425463T1 (de) * | 2003-06-06 | 2009-03-15 | Genentech Inc | Modulation der wechselwirkung zwischen hgf-beta- kette und c-met |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| US20050123932A1 (en) * | 2003-12-09 | 2005-06-09 | Mekbib Astatke | Nucleic acid-chelating agent conjugates |
| US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| RU2006135119A (ru) * | 2004-03-05 | 2008-04-10 | Аркемикс Корп. (Us) | Аптамеры к семейству цитокинов il-12 человека и их применение в качестве лекарственных средств для аутоиммунных заболеваний |
| JP2007532662A (ja) * | 2004-04-13 | 2007-11-15 | （オーエスアイ）アイテツク・インコーポレーテツド | 高分子量の立体的な基へ抱合された核酸アプタマー |
| WO2006135431A2 (en) * | 2004-10-19 | 2006-12-21 | Texas Tech University System | Inhibition of metallo-beta-lactamase by rna |
| CN101258241A (zh) * | 2005-07-05 | 2008-09-03 | 力博美科股份有限公司 | 与免疫球蛋白g结合的核酸及其利用方法 |
| US8637656B2 (en) * | 2005-07-05 | 2014-01-28 | Ribomic Inc. | Nucleic acid capable of binding to immunoglobulin G and use thereof |
| CN101374965B (zh) * | 2006-01-17 | 2013-08-14 | 私募蛋白质体公司 | 测试样品的多元化分析 |
| JP4698559B2 (ja) * | 2006-11-24 | 2011-06-08 | Ｎｅｃソフト株式会社 | ウサギ由来のＩｇＧ抗体に結合性を有する核酸分子 |
| US20110136099A1 (en) | 2007-01-16 | 2011-06-09 | Somalogic, Inc. | Multiplexed Analyses of Test Samples |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
| CA2729306C (en) | 2008-07-08 | 2015-08-18 | Oncomed Pharmaceuticals, Inc. | Notch-binding agents and antagonists and methods of use thereof |
| WO2010129666A1 (en) * | 2009-05-05 | 2010-11-11 | Altermune Technologies, Llc | Chemically programmable immunity |
| US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| US8772259B2 (en) | 2010-02-12 | 2014-07-08 | Ribomic Inc. | Aptamer to FGF2 and use thereof |
| SMT201700139T1 (it) | 2010-02-24 | 2017-05-08 | Immunogen Inc | Immunoconiugati contro il recettore 1 del folato e relativi usi |
| MY177062A (en) | 2010-03-12 | 2020-09-03 | Debiopharm Int Sa | Cd37-binding molecules and immunoconjugates thereof |
| WO2011125458A1 (ja) | 2010-04-02 | 2011-10-13 | 富士レビオ株式会社 | 抗癌剤の効果の診断用マーカー |
| WO2012014890A1 (ja) * | 2010-07-26 | 2012-02-02 | Ｎｅｃソフト株式会社 | ｃ－Ｍｅｔ結合核酸分子およびその用途 |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| JP2014503511A (ja) * | 2010-12-10 | 2014-02-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｍｒｉによる標的分子イメージングのためのｆ−１９核標識アプタマー |
| US20140301989A1 (en) * | 2011-06-17 | 2014-10-09 | Brian Johnstone | Methods for increasing the potency and efficacy of stem cells |
| GB201114662D0 (en) | 2011-08-24 | 2011-10-12 | Altermune Technologies Llc | Chemically programmable immunity |
| WO2013118877A1 (ja) * | 2012-02-10 | 2013-08-15 | 株式会社ジャパニック | 非ヒト幹細胞の培養上清を原材料とする化粧品又は皮膚再生促進剤、及びタンパク質のイオン導入方法 |
| WO2013155686A1 (zh) * | 2012-04-18 | 2013-10-24 | Wang Lemin | 整合素β亚基在诊断静脉血栓栓塞中的应用 |
| CN104388422B (zh) * | 2014-10-24 | 2017-08-25 | 集美大学 | 寡核苷酸序列及其制备方法与应用 |
| KR20200068647A (ko) * | 2017-08-11 | 2020-06-15 | 시티 오브 호프 | 트랜스페린 수용체 (TfR)에 대한 RNA 앱타머 |
| MX2021009742A (es) | 2019-02-15 | 2021-12-10 | Editas Medicine Inc | Celulas asesinas naturales (nk) modificadas para inmunoterapia. |
| CN114853869B (zh) * | 2019-12-10 | 2023-12-26 | 湖南赛奥维生物技术有限公司 | 一种碱性成纤维细胞生长因子替代物及其组合物和应用 |
| US20250262301A1 (en) | 2020-10-26 | 2025-08-21 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
| CA3214473A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
| MX2023011927A (es) | 2021-04-07 | 2023-10-23 | Century Therapeutics Inc | Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas. |
| AU2022253223A1 (en) | 2021-04-07 | 2023-09-28 | Century Therapeutics, Inc. | Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof |
| US20240293543A1 (en) | 2021-06-23 | 2024-09-05 | Editas Medicine, Inc. | Engineered cells for therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3546806C2 (enExample) | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
| WO1989006694A1 (en) | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| US5683867A (en) * | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
| US5731424A (en) * | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
| US5472841A (en) * | 1990-06-11 | 1995-12-05 | Nexstar Pharmaceuticals, Inc. | Methods for identifying nucleic acid ligands of human neutrophil elastase |
| US5874218A (en) * | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
| EP1695978A1 (en) | 1990-06-11 | 2006-08-30 | Gilead Sciences, Inc. | Nucleic acid ligands |
| US5837834A (en) * | 1990-06-11 | 1998-11-17 | Nexstar Pharmaceuticals, Inc. | High affinity HKGF nucleic acid ligands and inhibitors |
| AU1435492A (en) | 1991-02-21 | 1992-09-15 | Gilead Sciences, Inc. | Aptamer specific for biomolecules and method of making |
| CA2102595C (en) * | 1991-05-10 | 2003-01-14 | Paolo Comoglio | Truncated forms of the hepatocyte growth factor (hgf) receptor |
| US5756291A (en) * | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
| DE69334159D1 (de) * | 1992-09-18 | 2007-09-13 | Us Gov Health & Human Serv | Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen |
| WO1995007364A1 (en) * | 1993-09-08 | 1995-03-16 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands and improved methods for producing the same |
| EP0828849B1 (en) * | 1995-06-02 | 2006-10-25 | Gilead Sciences, Inc. | High-affinity oligonucleotide ligands to pdgf |
-
1999
- 1999-07-29 US US09/364,539 patent/US6344321B1/en not_active Expired - Fee Related
-
2000
- 2000-07-24 EP EP00948923A patent/EP1203007B1/en not_active Expired - Lifetime
- 2000-07-24 WO PCT/US2000/020139 patent/WO2001009159A1/en not_active Ceased
- 2000-07-24 JP JP2001513966A patent/JP2003506024A/ja active Pending
- 2000-07-24 CA CA002381004A patent/CA2381004A1/en not_active Abandoned
-
2006
- 2006-08-22 US US11/508,024 patent/US20070010473A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003506024A5 (enExample) | ||
| JP2004511201A5 (enExample) | ||
| Maric et al. | Bone morphogenetic protein‐7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats | |
| DE3049831C2 (de) | Vektoren enthaltend eine f}r das Oberfl{chenantigen des Hepatites B-Virus kodierende Nucleotidsequenz, Verwendung dieser Vektoren zur Herstellung von Peptiden, Impfstoffe enhaltend dabei erhaltende Peptide als Antigen | |
| JP2002535015A5 (enExample) | ||
| WO2005021707A3 (en) | Severe acute respiratory syndrome dna vaccine compositions and methods of use | |
| JP2002541233A5 (enExample) | ||
| JP2011530599A5 (enExample) | ||
| DE59913833D1 (de) | Strukturprotein von aav, seine herstellung und verwendung | |
| CN108220293A (zh) | 一种小干扰核酸和药物组合物及其用途 | |
| AU7194101A (en) | Treatment of glycogen storage disease type ii | |
| Ulrich et al. | Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury | |
| WO2005055948A3 (en) | Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders | |
| JP2003505111A5 (enExample) | ||
| WO2004050027A3 (en) | Materials and methods for treating ocular-related disorders | |
| Jouet et al. | Exon 2 of the gene for neural cell adhesion molecule Ll is alternatively spliced in B cells | |
| DE59709915D1 (de) | Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung | |
| JP2004527469A5 (enExample) | ||
| JPWO2023015309A5 (enExample) | ||
| Zhang et al. | Skin tumorigenesis and Ki‐ras and Ha‐ras mutations in tumors from adult mice exposed in utero to 3′‐azido‐2′, 3′‐dideoxythymidine | |
| Gupta et al. | Single‐dose pharmacokinetics and tolerability of pegylated interferon‐α2b in young and elderly healthy subjects | |
| JP2004201692A5 (enExample) | ||
| WO2001096397A3 (en) | Cd154 variants and uses thereof | |
| McMahon et al. | Using peptide nucleic acids as gene-expression modifiers to reduce β-amyloid levels | |
| Esteban et al. | The impact of rapid evolution of the hepatitis viruses |